Nucleome Therapeutics

About:

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases

Website: https://nucleome.com/

Twitter/X: NucleomeTx

Top Investors: Creative Destruction Lab (CDL), Oxford Science Enterprises, British Patient Capital, Pfizer Venture Investments, M Ventures

Description:

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 95% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. We have the unique ability to link these variants to gene function and map disease pathways. Our cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types. This enables us to discover and develop novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Our ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford and backed by investment from Oxford Sciences Innovation. For more information, please visit www.nucleome.com.